Highlights

Nostrum Biodiscovery News

NBD AT THE SBDD CONFERENCE

NBD has attended the SBDD conference in Lausanne which aims to discuss about computational methods as effective tools for drug discovery.

More Info

ASTRAZENECA ACCELERATES PAR2 USING PELE

AstraZeneca in collaboration with Heptares Therapeutic, has made significant progress with the new target called PAR2.

More Info

SUCCESSFUL MEETINGS IN SAN DIEGO!

NBD is running up its drug discovery programmes due to the extraordinary contacts at the BIO 2017.

More Info

NBD AT THE ACCIO INVESTMENT FORUM

NBD has been selected as one of the seven most innovative companies among +100 SMEs.

More Info

NBD JOINS BARCELONA BIOINFORMATICS (BIB)

NBD joins Barcelona Bioinformatics (BIB), established to meet synergies between biology and computer science.

More Info

NBD GETS FUNDED BY CDTI - NEOTEC

NBD has obtained a NEOTEC grant, one of the top-tier funding programmes focussed on highly innovative SMEs.

More Info

NBD JOINS CATALONIABIO NETWORK

NBD has recently joined CataloniaBio, the catalan association formed by biotech and pharmaceutical companies

More Info

PELE FEATURED AS A TIER-1 TOOL BY ASTRAZENECA

AstraZeneca positioning PELE as a tool applicable for rapid drug design cycles for binding mode and induced fit prediction.

More Info

MARENOSTRUM IV TO BE DEPLOYED IN 2017

NBD's stakeholder, the Barcelona Supercomputing Center has purchased the new supercomputer from IBM, which will integrate those of Lenovo, Intel and Fujitsu.

More Info

NBD SOON TO HAVE ONE OF THE BEST PPD CODES

NBD soon to have one of the highest-ranked protein-protein docking programs as determined in the Critical Assessment of Prediction of Interactions (CAPRI)

More Info

PELE RANKED AS TOP TIER IN THE 2014 CSAR

PELE ranked as top tier in the 2014 Community Structure Activity Resource blind test, set up by U.Michigan with unpublished data from GSK.

More Info

IMPROVING CURRENT NUCLEIC ACID FORCE-FIELDS

NBD’s Chairman, Modesto Orozco has recently led a coordinated effort to improve current nucleic acid force-fields.

MORE INFO

FIRST TESTS WITH CHEMISTRIX DATABASE

The first Proof of Concept test with an undiscloseed GPCR target have yielded active compounds synthesized out of the ChemistriX database. This is the first proof of the value of this database for in silico hit generation.

More Info
1 2 3 4